The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

WEDNESDAY, Sept. 25, 2024 (HealthDay News) -- During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Sen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes ...

Novo Nordisk CEO Lars Fruergaard Jørgensen, however, said that lowering the prices could result in unintended consequences ...

Patients taking Ozempic were about 60% less likely to have an opioid overdose compared to those taking other diabetes drugs.

Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices ...